{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:56:15Z","timestamp":1781794575013,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":31,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16110-2","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T04:52:56Z","timestamp":1779079976000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of perioperative chemotherapy and neoadjuvant chemoradiotherapy (CRT) in locally advanced resectable distal esophageal\/esophagogastric junction (EGJ) adenocarcinomas"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0816-5397","authenticated-orcid":false,"given":"Buket","family":"\u015eahin \u00c7elik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-6483","authenticated-orcid":false,"given":"G\u00f6zde","family":"A\u011fda\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3149-6133","authenticated-orcid":false,"given":"Vahap","family":"Gen\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"16110_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa05553","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320. https:\/\/doi.org\/10.1056\/NEJMoa05553.","journal-title":"N Engl J Med"},{"key":"16110_CR2","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"S-E Al-Batran","year":"2019","unstructured":"Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2\/3 trial. Lancet. 2019;393:1948\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(18)32557-1.","journal-title":"Lancet"},{"key":"16110_CR3","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074\u201384. https:\/\/doi.org\/10.1056\/NEJMoa1112088.","journal-title":"N Engl J Med"},{"key":"16110_CR4","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12885-017-3386-2","volume":"17","author":"JV Reynolds","year":"2017","unstructured":"Reynolds JV, Preston SR, O\u2019Neill B, Baeksgaard L, Griffin SM, Mariette C, et al. ICORG 10\u201314: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer. 2017;17:401. https:\/\/doi.org\/10.1186\/s12885-017-3386-2.","journal-title":"BMC Cancer"},{"key":"16110_CR5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.20.03614","volume":"39","author":"BM van der Eyck","year":"2021","unstructured":"van der Eyck BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, Shapiro J, van Hagen P, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: A randomized controlled CROSS trial. J Clin Oncol. 2021;39:1995\u20132004. https:\/\/doi.org\/10.1200\/JCO.20.03614.","journal-title":"J Clin Oncol"},{"key":"16110_CR6","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1245\/s10434-017-5830-6","volume":"24","author":"T Leong","year":"2017","unstructured":"Leong T, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D, et al. TOPGEAR: A randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: Interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG. Ann Surg Oncol. 2017;24:2252\u20138. https:\/\/doi.org\/10.1245\/s10434-017-5830-6.","journal-title":"Ann Surg Oncol"},{"key":"16110_CR7","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Esophageal and Esophagogastric Junction Cancers. Version 4.2025. NCCN.org."},{"issue":"7","key":"16110_CR8","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S1470-2045(11)70142-5","volume":"12","author":"KM Sjoquist","year":"2011","unstructured":"Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681\u201392. https:\/\/doi.org\/10.1016\/S1470-2045(11)70142-5.","journal-title":"Lancet Oncol"},{"key":"16110_CR9","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1016\/j.ejca.2013.05.029","volume":"49","author":"U Ronellenfitsch","year":"2013","unstructured":"Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE, et al. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: Systematic review with meta-analysis combining individual patient and aggregate data. Eur J Cancer. 2013;49:3149\u201358. https:\/\/doi.org\/10.1016\/j.ejca.2013.05.029.","journal-title":"Eur J Cancer"},{"key":"16110_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NCT, Lordick F. Gastric cancer Lancet. 2020;396:635\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(20)31288-5.","journal-title":"Gastric cancer Lancet"},{"issue":"10","key":"16110_CR11","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, et al. ESMO Clinical Practice Guideline for the diagnosis and treatment of gastric and gastro-oesophageal junction cancers. Ann Oncol. 2022;33(10):1005\u201320. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.004.","journal-title":"Ann Oncol"},{"key":"16110_CR12","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer: Long-term results of the CROSS trial. Lancet Oncol. 2015;16:1090\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(15)00040-6.","journal-title":"Lancet Oncol"},{"key":"16110_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1200\/JCO.2001.19.2.305","volume":"19","author":"SG Urba","year":"2001","unstructured":"Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305\u201313. https:\/\/doi.org\/10.1200\/JCO.2001.19.2.305.","journal-title":"J Clin Oncol"},{"key":"16110_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1056\/NEJMoa1805101","volume":"380","author":"C Mariette","year":"2019","unstructured":"Mariette C, Markar SR, Dabakuyo-Yonli TS, et al. Hybrid minimally invasive esophagectomy for esophageal cancer. N Engl J Med. 2019;380:152\u201362. https:\/\/doi.org\/10.1056\/NEJMoa1805101.","journal-title":"N Engl J Med"},{"key":"16110_CR15","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1056\/NEJM199608153350702","volume":"335","author":"TN Walsh","year":"1996","unstructured":"Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462\u20137. https:\/\/doi.org\/10.1056\/NEJM199608153350702.","journal-title":"N Engl J Med"},{"key":"16110_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1470-2045(17)30043-8","volume":"18","author":"D Cunningham","year":"2017","unstructured":"Cunningham D, Stenning SP, Smyth EC, Okines AF, Allum WH, Rowley S, et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): Primary analysis results of a multicentre, open-label, randomised phase 2\u20133 trial. Lancet Oncol. 2017;18:357\u201370. https:\/\/doi.org\/10.1016\/S1470-2045(17)30043-8.","journal-title":"Lancet Oncol"},{"key":"16110_CR17","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1186\/s12885-016-2564-y","volume":"16","author":"J Hoeppner","year":"2016","unstructured":"Hoeppner J, Lordick F, Brunner T, Glatz T, Bronsert P, R\u00f6thling N, et al. Prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer. 2016;16:503. https:\/\/doi.org\/10.1186\/s12885-016-2564-y.","journal-title":"BMC Cancer"},{"key":"16110_CR18","doi-asserted-by":"publisher","first-page":"580","DOI":"10.4143\/crt.2023.812","volume":"56","author":"L Mineur","year":"2024","unstructured":"Mineur L, Plat F, Desseigne F, Deplanque G, Belkacemi M, Moureau-Zabotto L, et al. NESC multicenter phase II trial in the preoperative treatment of gastric adenocarcinoma with chemotherapy (docetaxel\u2013cisplatin\u20135FU\u2009+\u2009lenograstim) followed by chemoradiation based on 5FU and oxaliplatin and surgery. Cancer Res Treat. 2024;56:580\u20139. https:\/\/doi.org\/10.4143\/crt.2023.812.","journal-title":"Cancer Res Treat"},{"key":"16110_CR19","doi-asserted-by":"publisher","unstructured":"Li Z, Shan F, Wang Y, Zhang Y, Zhang L, Li S, et al. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis. PLoS ONE. 2018;13e0189294. https:\/\/doi.org\/10.1371\/journal.pone.0189294.","DOI":"10.1371\/journal.pone.0189294"},{"key":"16110_CR20","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1097\/SLA.0b013e3182a66588","volume":"258","author":"CL Donohoe","year":"2013","unstructured":"Donohoe CL, O\u2019Farrell NJ, Grant T, King S, Clarke L, Muldoon C, et al. Classification of pathologic response to neoadjuvant therapy in esophageal and junctional cancer: Assessment of existing measures and proposal of a novel 3-point standard. Ann Surg. 2013;258:784\u201392. https:\/\/doi.org\/10.1097\/SLA.0b013e3182a66588.","journal-title":"Ann Surg"},{"key":"16110_CR21","doi-asserted-by":"publisher","first-page":"5062","DOI":"10.1200\/JCO.2009.22.2083","volume":"27","author":"WH Allum","year":"2009","unstructured":"Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:5062\u20137. https:\/\/doi.org\/10.1200\/JCO.2009.22.2083.","journal-title":"J Clin Oncol"},{"key":"16110_CR22","doi-asserted-by":"publisher","unstructured":"Gaber CE, Sarker J, Abdelaziz AI, Okpara E, Lee TA, Klempner SJ, et al. Pathologic complete response in patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: A systematic review and meta-analysis. Cancer Med. 2024;13e7076. https:\/\/doi.org\/10.1002\/cam4.7076.","DOI":"10.1002\/cam4.7076"},{"key":"16110_CR23","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1200\/JCO.1999.17.10.327","volume":"17","author":"DH Ilson","year":"1999","unstructured":"Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, et al. Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol. 1999;17:3270\u20135. https:\/\/doi.org\/10.1200\/JCO.1999.17.10.327.","journal-title":"J Clin Oncol"},{"key":"16110_CR24","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1200\/JCO.2005.00.034","volume":"23","author":"M Stahl","year":"2005","unstructured":"Stahl M, Stuschke M, Lehmann N, Meyer H-J, Walz MK, Seeber S, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310\u20137. https:\/\/doi.org\/10.1200\/JCO.2005.00.034.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16110-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16110-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16110-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:40:57Z","timestamp":1781793657000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16110-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16110"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16110-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was reviewed and approved by the Clinical Research Ethics Committee of the Van Training and Research Hospital (approval number: GOKAEK-2025-09-20, dated 07 November 2025).Local ethics committee approval was waived for the participating centers other than the coordinating center, in accordance with national regulations governing multicenter retrospective studies, and ethics approval was obtained in accordance with local regulations for all participating centers. Due to the retrospective nature of the study and the use of anonymized patient data, the requirement for informed consent was waived by the ethics committee. All procedures were conducted in accordance with the ethical standards of the institutional and national research committees and with the 1964 Declaration of Helsinki and its subsequent amendments.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. No individual, identifiable, or patient-specific data are included in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"758"}}